Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor

Summary

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving imatinib mesylate before surgery may shrink the tumor so that it can be removed. PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating patients with locally advanced gastrointestinal stromal tumor.

Timeline

Start

2005-02

Primary completion

—

Completion

—

Drugs

Indications